Kitazato

Kitazato EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Kitazato (368A.T) as of Nov 17, 2026 is 8.78. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was 8.75 — a change of 0.27% (higher).

EV/EBITDA

8.78

YoY

0.27%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Kitazato is 2025 8.78 . EV/EBITDA (Enterprise Value to EBITDA) of Kitazato was 2024 8.75 . It decreases by 0.27% higher compared to the previous year.

The Kitazato EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2023
10.55 JPY
Jan 1, 2024
8.75 JPY
Jan 1, 2025
8.78 JPY
The Kitazato EV/EBITDA history
YEAREV/EBITDAYoY
8.78+0.27%
8.75-17.06%
10.55—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kitazato Stock analysis

What does Kitazato do? Kitazato Corp manufactures and sells medical devices, reagents, and related products for infertility treatment, specializing in reproductive engineering technology for artificial insemination, in vitro fertilization, and cell cryopreservation. The company produces consumables such as medical equipment and reagents used in in vitro fertilization and intracytoplasmic sperm injection, including media, cryo devices, medical devices, and micro tools. Kitazato Corp distributes its products globally, serving markets in Japan, Europe, the United States, China, and India, with a focus on research reagents and medical equipment for infertility treatment. The firm also manufactures and sells medical equipment parts, provides genetic testing services, and offers medical equipment for the elderly. Additionally, Kitazato Corp engages in market research, acquisition of local licenses, and contract management of living cells, expanding its reach into regenerative medicine and related fields. These services and products target healthcare providers, fertility clinics, and research institutions worldwide. Kitazato Corp's revenue streams include the sale of consumables, medical devices, and reagents, as well as genetic testing and contract management services. The company's global distribution network supports sales across key regions, with a strong emphasis on infertility treatment solutions and regenerative medicine technologies. Kitazato is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kitazato stock

EV/EBITDA (Enterprise Value to EBITDA) of Kitazato is 8.78 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of Kitazato changed from 8.75 to 8.78, representing a 0.27% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Kitazato since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Kitazato with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Kitazato

All Key Metrics — Kitazato